Search Result

Results for "

PRMTs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Akt (2) Amine N-methyltransferase (2) Androgen Receptor (1) AP-1 (2) Apoptosis (27) ATP-binding cassette (ABC) transporters (1) Bcl-2 Family (4) BCL6 (1) c-Myc (2) Caspase (2) CDK (2) COX (2) Cytochrome P450 (2) Discoidin Domain Receptor (1) DNA/RNA Synthesis (2) Drug Derivative (2) E3 Ligase Ligand-Linker Conjugates (1) Early 2 Factor (E2F) (1) EGFR (1) Epigenetic Reader Domain (1) ERK (2) Fluorescent Dye (1) Fungal (1) HDAC (2) Histone Acetyltransferase (1) Histone Demethylase (2) Histone Methyltransferase (187) HSP (1) IAP (2) Isotope-Labeled Compounds (1) JNK (2) KLF (2) Ligands for Target Protein for PROTAC (4) LYTACs (1) MDM-2/p53 (2) METTL3 (1) NF-κB (2) NO Synthase (2) p38 MAPK (2) PAK (1) Parasite (3) Phosphodiesterase (PDE) (3) PI3K (2) PKA (2) Potassium Channel (1) PROTACs (8) Proteasome (1) Proteasome Cap Targeting Chimeras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (11) SARS-CoV (2) Sirtuin (1) Small Interfering RNA (siRNA) (24) Survivin (2) Target Protein Ligand-Linker Conjugates (1)
By Research Areas:	Cancer (190) Infection (6) Inflammation/Immunology (10) Metabolic Disease (4) Neurological Disease (2)
Oligonucleotides:	Aptamers (2) Rat Pre-designed siRNA Sets (8) Mouse Pre-designed siRNA Sets (8) Human Pre-designed siRNA Sets (8) siRNAs (24)

222

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139611

Navlimetostat 3 Publications Verification MRTX-1719; BMS-986504	Histone Methyltransferase	Cancer
Navlimetostat is a potent, orally active, selective *PRMT5-MTA* complex inhibitor, with IC₅₀ of 3.6 and 20.5 nM for *PRMT5-MTA* and *PRMT5. Navlimetostat binds to the PRMT5-MTA* complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .

HY-19615

MS023 20+ Cited Publications	Histone Methyltransferase	Cancer
MS023, a chemical probe, is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC₅₀s of 30, 119, 83, 4 and 5 nM for *PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8*, respectively .

HY-128717A

GSK3368715 dihydrochloride 15+ Cited Publications EPZ019997 dihydrochloride	Histone Methyltransferase	Cancer
GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC₅₀=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .

HY-12970A

EPZ020411 hydrochloride 5+ Cited Publications	Histone Methyltransferase Apoptosis	Cancer
EPZ020411 hydrochloride is a selective inhibitor of *PRMT6* with an IC₅₀ of 10 nM, it has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 hydrochloride can be used for the research of cancer .

HY-128717

GSK3368715 15+ Cited Publications EPZ019997	Histone Methyltransferase	Cancer
GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC₅₀=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .

HY-107777

LLY-283 5+ Cited Publications	Histone Methyltransferase	Cancer
LLY-283, a chemical probe, is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC₅₀ of 22 nM and a K_d of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity .

HY-18962

AMI-1 5+ Cited Publications	Histone Methyltransferase	Cancer
AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC₅₀s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding .

HY-12970

EPZ020411 5+ Cited Publications	Histone Methyltransferase Apoptosis	Cancer
EPZ020411 is a selective inhibitor of *PRMT6* with an IC₅₀ of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer .

HY-19615B

MS023 dihydrochloride 20+ Cited Publications	Histone Methyltransferase	Cancer
MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC₅₀s of 30, 119, 83, 4 and 5 nM for *PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8*, respectively .

HY-173561

MS115	PROTACs Histone Methyltransferase	Cancer
MS115 is a selective *PRMT5/MEP50* PROTAC degrader, with DC₅₀ values of 17.4 nM and 11.3 nM for PRMT5 and MEP50, respectively. MS115 promotes PRMT5/MEP50 ubiquitination and degradation. MS115 shows anticancer activity against breast cancer .

HY-151576

PRMT5:MEP50 PPI	Histone Methyltransferase	Cancer
PRMT5:MEP50 PPI is a novel PRMT5:MEP50 protein-protein interaction (PRMT5:MEP50 PPI) inhibitor, shows anti-tumor activity and anti-proliferative activity of lung and prostate cancer cells .

HY-139611C

Navlimetostat hydrochloride 3 Publications Verification MRTX-1719 hydrochloride; BMS-986504 hydrochloride	Histone Methyltransferase	Cancer
Navlimetostat hydrochloride is a potent, orally active, selective *PRMT5-MTA* complex inhibitor, with IC₅₀s of 3.6 and 20.5 nM for *PRMT5-MTA* and *PRMT5. Navlimetostat hydrochloride binds to the PRMT5-MTA* complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .

HY-173557

PRMT7-IN-2	Histone Methyltransferase Apoptosis	Cancer
PRMT7-IN-2 (A33) is a selective *PRMT7* inhibitor with an IC₅₀ of 0.50 μM. PRMT7-IN-2 arrests cell cycle at G0/G1 phase, induces cell apoptosis, and inhibits cell growth in vivo and in vitro. PRMT7-IN-2 decreases the monomethylarginine level of *PRMT7, increases expression of epithelial marker (E-cadherin, and reduces expression of mesenchymal markers such as N-cadherin, Vimentin, and ZEB2* .

HY-111213

PRMT5-IN-20	Histone Methyltransferase	Cancer
PRMT5-IN-20 is a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with anti-tumor activity .

HY-132309

BRD0639 1 Publications Verification	Histone Methyltransferase	Cancer
BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities .

HY-112165

PRMT5-IN-2	Histone Methyltransferase	Cancer
PRMT5-IN-2 is a rotein arginine methyltransferase 5 (PRMT5) inhibitor extracted from patent WO2018130840A1, compound 3 .

HY-124131

DS-437 1 Publications Verification	Histone Methyltransferase	Inflammation/Immunology Cancer
DS-437 is a dual *PRMT5/7* inhibitor (IC₅₀s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC₅₀s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3 .

HY-18962A

AMI-1 free acid 5+ Cited Publications	Histone Methyltransferase	Cancer
AMI-1 free acid is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC₅₀s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 free acid exerts PRMTs inhibitory effects by blocking peptide-substrate binding .

HY-W280124

PRMT9-IN-1	Histone Methyltransferase	Cancer
PRMT9-IN-1 is a *PRMT9* inhibitor. PRMT9-IN-1 can be used in the research of hematological cancer .

HY-Q36691

PRMT5-IN-30	Histone Methyltransferase	Cancer
PRMT5-IN-30 (compound 17) is a potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 0.33 μM and a K_d of 0.987 μM. PRMT5-IN-30 exhibits a broad selectivity against a panel of other methyltransferases. PRMT5-IN-30 inhibits PRMT5 mediated SmD3 methylation .

HY-147185

PRMT7-IN-1	Histone Methyltransferase	Cancer
PRMT7-IN-1 (Compound 14) is a *PRMT7* inhibitor with an IC₅₀ of 2.1 μM. PRMT7-IN-1 shows anticancer activity against different cancer cells .

HY-160865

PRMT5-IN-35	Histone Methyltransferase	Cancer
PRMT5-IN-35 (Compound 87) is a potent, selective and orally active *PRMT5* inhibitor with an IC₅₀ value of 1 nM. PRMT5-IN-35 can be used in cancer research .

HY-126256A

PRMT5-IN-1 hydrochloride	Histone Methyltransferase	Cancer
PRMT5 IN-1 hydrochloride (compound 9), a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 11 nM for PRMT5/MEP50. PRMT5 IN-1 hydrochloride can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .

HY-159728

*PROTAC PRMT3 degrader 1*	PROTACs Histone Methyltransferase Apoptosis Early 2 Factor (E2F) c-Myc	Cancer
PROTAC PRMT3 degrader 1 is a selective *PRMT3* PROTAC degrader with a DC₅₀ of 2.566 μM. PROTAC PRMT3 degrader 1 forms a ternary complex with MDM2 E3 ubiquitin ligase to induce proteasomal and neddylation-dependent degradation of PRMT3. PROTAC PRMT3 degrader 1 activates intrinsic apoptosis, endoplasmic reticulum stress signaling pathways. PROTAC PRMT3 degrader 1 downregulates E2F, MYC, oxidative phosphorylation pathways. PROTAC PRMT3 degrader 1 reduces cellular asymmetric dimethylarginine (ADMA) levels. PROTAC PRMT3 degrader 1 inhibits acute leukemia cell growth. PROTAC PRMT3 degrader 1 acts with glycolysis inhibitor 2-DG to reduce ATP production, induce intrinsic apoptosis, drive synergistic antiproliferative effects. PROTAC PRMT3 degrader 1 can be used for the research of acute leukemia .

HY-152236

PRMT6-IN-3	Histone Methyltransferase Apoptosis	Cancer
PRMT6-IN-3 (compound 25) is a selective *PRMT6* inhibitor with an IC₅₀ value of 192 nM. PRMT6-IN-3 can induce apoptosis in cancer cells and has anticancer activity .

HY-172769

CM112	Histone Methyltransferase	Cancer
CM112 is a selective protein arginine methyltransferase 1 (PRMT1) degrader by tethering hydrophobic tag, adamantane, to MS023 with a 5-PEG linker. CM112 induces the degradation of PRMT1 in various solid cancer cell lines. CM112 can also target the nonenzymatic function of PRMT1 by downregulating the stability of the orphan receptor TR3. CM112 is promising for research of cancers .

HY-134883

PRMT5-IN-4	Histone Methyltransferase	Cancer
PRMT5-IN-4 is a *PRMT5* inhibitor. PRMT5-IN-4 is applicable for cancer research .

HY-155050

PRMT5-IN-31	Apoptosis Histone Methyltransferase	Cancer
PRMT5-IN-31 (Compound 3m) is a selective *PRMT5* inhibitor (IC₅₀: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T_1/2: 132.4 min) .

HY-136809

PRMT6-IN-2	Histone Methyltransferase	Cancer
PRMT6-IN-2 (compound 2) is a dual inhibitor of protein arginine methyltransferase PRMT6 and CARM1 with an IC50 of 30 nM. PRMT6 is abnormally expressed in many cancer cells, and PRMT6-IN-2-based derivatives have potential anticancer activity.

HY-158143

AZD3470	Histone Methyltransferase	Cancer
PRMT5-IN-34 (Compound C) is an inhibitor of MTA-cooperative Protein arginine methyltransferase 5 (PRMT5/MAT) .

HY-126256

PRMT5-IN-1	Histone Methyltransferase	Cancer
PRMT5 IN-1, a hemiaminal, is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC₅₀ of 11 nM for PRMT5/MEP50. PRMT5 IN-1 can be converted to aldehydes and react with C449 to form covalent adducts under physiological conditions .

HY-174983

PRMT5-MTA-IN-6	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-6 (Compound 31) is a selective MTA-cooperative *PRMT5* inhibitor. PRMT5-MTA-IN-6 exhibits potent inhibitory activity against *PRMT5・MTA* (IC₅₀: 6.6 nM). PRMT5-MTA-IN-6 selectively inhibits the growth of MTAP-deleted HCT-116 cells (IC₅₀: 319 nM). PRMT5-MTA-IN-6 can be used in the research of MTAP-deleted tumors .

HY-175821

PRMT1-IN-3	Histone Methyltransferase Apoptosis	Cancer
PRMT1-IN-3 is a potent protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC₅₀ of 4.11 μM. PRMT1-IN-3 inhibits *PRMT6* and *PRMT8* with IC₅₀s of 23.3 and 30.1 μM. PRMT1-IN-3 suppresses asymmetric dimethylarginine (ADMA) levels and histone H4R3me2a modification in triple-negative breast cancer (TNBC) cells. PRMT1-IN-3 induces cell cycle arrest, apoptosis, and inhibits migration and colony formation in MDA-MB-231 cells. PRMT1-IN-3 acts as chemotherapeutic sensitizers for Paclitaxel (HY-B0015). PRMT1-IN-3 can be used for the study of TNBC .

HY-176231

PRMT5-IN-51	Histone Methyltransferase	Cancer
PRMT5-IN-51 (compound 16–19F) is a potent *PRMT5* inhibitor. PRMT5-IN-51 shows antiproliferative activity .

HY-178028

PRMT5-IN-53	Histone Methyltransferase	Cancer
PRMT5-IN-53 is a gut-restricted and orally active *PRMT5* inhibitor with pIC₅₀s of ≥ 9.7 against hPRMT5 and mPRMT5. PRMT5-IN-53 binds to the PRMT5:MEP50 complex with a K_D of 11.3 pM. PRMT5-IN-53 effectively inhibits PRMT5 locally in the intestines of mice, significantly reducing the number and area of polyps, while avoiding systemic hematological toxicity (such as anemia, neutropenia). PRMT5-IN-53 can be used for the study of colorectal cancer especially for familial adenomatous polyposis (FAP) .

HY-176702

PRMT5-MTA-IN-5	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-5 (Compound 7) is an orally active, irreversible PRMT5-MTA complex (PRMT5•MTA) inhibitor (IC₅₀=1.15 nM). PRMT5-MTA-IN-5 blocks arginine methylation and inhibits ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-5 potently inhibits proliferation in MTAP-deficient tumor cells. PRMT5-MTA-IN-5 is promising for research of MTAP-deficient solid tumors, such as liver, breast, and pancreatic cancers .

HY-168263

PRMT5-IN-45	Histone Methyltransferase Apoptosis	Cancer
PRMT5-IN-45 (compound 36) is a potent and selective *PRMT5* inhibitor with an IC₅₀ of 3 nM. PRMT5-IN-45 potently reduces the level of symmetric dimethylarginines (sDMA) and inhibits the proliferation of MOLM-13 cell lines by inducing apoptosis and cell cycle arrest .

HY-176534

PRMT5-IN-52	Histone Methyltransferase	Cancer
PRMT5-IN-52 (Compound 17) is a non-nucleoside Protein Arginine Methyltransferase 5 (PRMT5) inhibitor with inhibitory rates of 20.2% at 10 μM. PRMT5-IN-52 has potent antitumor activity, promising for research of cancers, including lung, prostate cancer, and colorectal carcinoma .

HY-176701

PRMT5-MTA-IN-4	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC₅₀=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC₅₀=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .

HY-111030

PRMT1-IN-2	Histone Methyltransferase	Cancer
PRMT1-IN-2 (RM65) is a potent *PRMT1* inhibitor with an IC₅₀ of 55.4 μM. PRMT1-IN-2 shows histone hypomethylation in HepG2 cells .

HY-162003A

DCPT1061 hydrochloride	Histone Methyltransferase	Cancer
DCPT1061 hydrochloride has a strong inhibitory effect on *PRMT1, PRMT6, and PRMT8* in vitro, The epigenetic enzymes such as *PRMT3, PRMT4* and *PRMT5* had little inhibitory effect. DCPT1061 hydrochloride has antitumor effects .

HY-155154

PRMT4-IN-2	Histone Methyltransferase	Cancer
PRMT4-IN-2 (compound 55) is a pan-inhibitor of protein arginine methyltransferase (PRMT) with IC₅₀s of 92 nM (PRMT4), 436 nM (PRMT6), 460 nM (PRMT1), 823 nM ( PRMT8), 1.386 μM (PRMT3) .

HY-155154A

PRMT4-IN-3	Histone Methyltransferase	Cancer
PRMT4-IN-3 (compound 56) is a potent inhibitor of class I protein arginine methyltransferase (PRMT), targeting PRMT4 (IC₅₀: 37 nM) and PRMT4 (IC₅₀: 253 nM) .

HY-178274

SKLB06329	Histone Methyltransferase Apoptosis	Cancer
SKLB06329 is a potent selective Type I *PRMTs* inhibitor. SKLB06329 shows good selectivity for *PRMT6* (IC₅₀ = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research .

HY-18962R

AMI-1 (Standard)	Histone Methyltransferase	Cancer
AMI-1 (Standard) is the analytical standard of AMI-1. This product is intended for research and analytical applications. AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding .

HY-18962AR

AMI-1 free acid (Standard)	Histone Methyltransferase	Cancer
AMI-1 (free acid) (Standard) is the analytical standard of AMI-1 (free acid). This product is intended for research and analytical applications. AMI-1 free acid is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 free acid exerts PRMTs inhibitory effects by blocking peptide-substrate binding .

HY-159732

PRMT3-IN-4	Histone Methyltransferase	Cancer
PRMT3-IN-4 (intermediate 15) is a protein arginine methyltransferase 3 (PRMT3) inhibitor. PRMT3-IN-4 is an active control for HY-19715. PRMT3-IN-4 can be used to synthesize PROTACs targeting PRMT3. PRMT3-IN-4 can be used in leukemia-related research .

HY-171132

PRMT3-IN-5	Histone Methyltransferase
PRMT3-IN-5 (Compound 14) is an allosteric *PRMT3* inhibitor (IC₅₀: 291 nM). PRMT3-IN-5 can be used for investigating PRMT3's biological functions and disease associations .

HY-163592

PRMT5-IN-43	Histone Methyltransferase	Cancer
PRMT5-IN-43 (compound 4A) is a *PRMT5* inhibitor. PRMT5-IN-43 can be used in cancer research .

HY-163593

PRMT5-IN-44	Histone Methyltransferase	Cancer
PRMT5-IN-44 (compound 12) is a *PRMT5* inhibitor. PRMT5-IN-44 can be used in cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P3822

PRMT5-IN-23	Histone Methyltransferase	Cancer
PRMT5-IN-23 (compound 50) is an inhibitor of protein arginine methyltransferase 5 (PRMT5) with anti-tumor activity. *PRMT5* is a type of protein arginine methyltransferase, and is a new anti-tumor target related to epigenetic modification .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2420

Flavokawain A 2 Publications Verification	Chalcones Monophenols Flavonoids other families Classification of Application Fields Phenols Plants Disease Research Fields Source Classification Cancer	Apoptosis Histone Methyltransferase Cytochrome P450 Caspase Survivin IAP p38 MAPK PI3K NO Synthase COX JNK ERK Akt
Flavokawain A is a chalcone compound and an orally active inhibitor of *PRMT5* and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .

HY-N2420R

Flavokawain A (Standard)	Structural Classification Chalcones Monophenols Flavonoids other families Phenols Plants Source Classification	Reference Standards Apoptosis Histone Methyltransferase Cytochrome P450 Caspase Survivin IAP p38 MAPK PI3K NO Synthase COX JNK ERK Akt
Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .

Cat. No.	Product Name	Chemical Structure

HY-163587

PRMT5-IN-39-d3
PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active *PRMT5* inhibitor and can be used for study of cancer .

HY-163591

PRMT5-IN-36-d3
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research .

HY-172733S

PRMT5-MTA-IN-3-d3

PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

Cat. No.	Product Name		Classification

HY-147081

AS 1411 2 Publications Verification AGRO-100		Aptamers
AS 1411 (AGRO-100) is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. AS 1411 works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. AS 1411-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity .

HY-147081A

AS 1411 sodium 2 Publications Verification AGRO-100 sodium		Aptamers
AS 1411 (AGRO-100) sodium is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 sodium inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 sodium reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. S 1411 sodium works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. S 1411 sodium-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity

HY-RS11173

Prmt3 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11174

PRMT5 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT5 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11180

PRMT7 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT7 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11167

PRMT1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT1 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11177

PRMT6 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT6 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11186

PRMT9 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT9 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11170

PRMT2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT2 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11171

PRMT3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT3 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11185

Prmt8 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS19732

Prmt2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11181

Prmt7 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11172

Prmt3 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11183

PRMT8 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRMT8 Human Pre-designed siRNA Set A contains three designed siRNAs for PRMT8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS20467

Prmt9 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11169

Prmt1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11168

Prmt1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11184

Prmt8 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt8 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt8 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11175

Prmt5 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11176

Prmt5 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11178

Prmt6 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prmt6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prmt6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11182

Prmt7 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS26976

Prmt9 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS26228

Prmt2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Prmt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Prmt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11179

PRMT6 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
PRMT6 Rat Pre-designed siRNA Set A contains three designed siRNAs for PRMT6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks